Versameb Ltd, a Swiss biopharmaceutical company, closed a Seed financing round, bringing the total capital raised to date to CHF 5.3 million. Versameb Ltd is developing a technology platform for therapies, focusing on regenerative medicine through the local application of messenger ribonucleic acid (mRNA).
Versameb has a novel proprietary technology platform for optimized and tailored, local delivery of therapeutic proteins. The optimised molecules have the potential to increase therapeutic potency and improve their residence at the targeted site. This increases therapeutic windows of potential candidates for both addressing unmet medical needs and improving existing therapies. The Versameb platform can generate clinical candidates rapidly and can be applied in a broad variety of disease areas. Currently, the company is prioritizing the field of tissue regeneration in both acute and chronic conditions.
The proceeds will fund the extension of the platform technology, starting of pre-IND activities with the lead program and preclinical activities for additional regenerative medicine indications, and will secure the company’s corporate needs for organizational growth.
“We are very pleased and grateful that our company is enjoying strong support from Swiss and international private investors with both scientific and financial background” commented Prof. Dr. Friedrich Metzger, Versameb’s CEO. He added: “Thanks to our team, we were able to kick-start our operations rapidly and create substantial value in a short period of time. Our technology has the potential to address a broad variety of currently unmet medical needs. I look forward to an exciting discovery and development journey.”
(Press release)
Please login or sign up to comment.
Commenting guidelines